Clinical trials cost money and there will be a R&D tax refund. At our stage of running clinical trials, of course there will be negative cashflow and net losses for the financial year. This will again be ameliorated with the tax refund and soon we will also have the revenue generating S Bromide. Longer term, our fortunes will depend on getting one or more products to stage 3 and commercialisation. IMO there is nothing alarming in this report. Onwards and upwards, GLTA
Ann: Preliminary Final Report, page-6
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $751.1M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 43.0¢ | 40.5¢ | $3.179M | 7.658M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 83000 | 41.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.0¢ | 367540 | 8 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| BOT (ASX) Chart |